Mechanistically, SET over-expression and the resulting PP2A inhibition is critical for the maintenance of the leukemogenic program by BCR::ABL in CML [21, 27]. This evidence concerns the gene PTPA and chronic myelogenous leukemia, BCR-ABL1 positive.